علاج الخط الثاني لورم الظهارة المتوسطة الجنبية الظهاري بعد تقدم علاج الخط الأول

References

DOI: 10.1200/JCO-24-02425

• In patients with newly diagnosed epithelioid mesothelioma, ipilimumab plus nivolumab immunotherapy should be offered as a first-line systemic treatment option.
• In patients with epithelioid histology, pemetrexed plus platinum-based chemotherapy with or without bevacizumab may be offered as a first-line systemic treatment option.
• In patients who have received first-line immunotherapy, pemetrexed plus platinum with or without bevacizumab may be offered as an initial chemotherapy treatment option.
• In patients previously treated with chemotherapy, double-agent immunotherapy may be offered as a treatment option.
• In patients previously treated with chemotherapy, single-agent immunotherapy may be offered as a treatment option.